Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 23(6): 456-462, 2023 06.
Article
in English
| MEDLINE | ID: covidwho-2286674
ABSTRACT
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T. We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Receptors, Chimeric Antigen
/
COVID-19
/
Multiple Myeloma
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Clin Lymphoma Myeloma Leuk
Journal subject:
Neoplasms
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS